Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Artesunate/mefloquine - Drugs for Neglected Diseases Initiative Foundation

Drug Profile

Artesunate/mefloquine - Drugs for Neglected Diseases Initiative Foundation

Alternative Names: Artesunate-mefloquine; ASMQ FDC; Mefliam Plus; Mefloquine/artesunate

Latest Information Update: 30 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Drugs for Neglected Diseases Initiative Foundation
  • Developer Cipla; Drugs for Neglected Diseases Initiative Foundation; Oswaldo Cruz Foundation
  • Class Antimalarials; Artemisinins; Phytotherapies; Quinolines; Sesquiterpenes
  • Mechanism of Action Free radical stimulants; Sarcoplasmic reticulum calcium-transporting ATPase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Falciparum malaria

Most Recent Events

  • 30 Jul 2019 No development reported - Preregistration for Falciparum malaria in Laos, Philippines, Papua New Guinea, Indonesia, Kenya, Ghana, Ghana, Togo, Benin, Chad, Ivory Coast, Guinea, Senegal, Senegal, Democratic Republic of the Congo, Democratic Republic of the Congo, Malawi, Congo, Mali (PO)
  • 19 May 2017 Launched for Falciparum malaria in Cameroon and Thailand (PO) before May 2017 (DNDi website, May 2017)
  • 19 May 2017 Artesunate/mefloquine is still pending registration for Falciparum malaria in Laos, Philippines, Papua New Guinea, Indonesia, Kenya, Ghana, Benin, Togo, Chad, Ivory Coast, Republic of Guinea, Senegal, Democratic Republic of Congo, Malawi, Congo, and Mali (PO) (DNDi website, May 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top